Company intelligence / Profile preview

Xm Biologics

Providence, Rhode Island, United Statesidcrawl.com ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

XM Therapeutics has demonstrated proof-of-concept that its injectable ECM biologic products can alter dysfunctional extracellular matrix composition to reduce scar size and improve muscle contractility in preclinical heart models. The company remains at the pre-clinical stage with ongoing studies focused on cardiovascular and respiratory diseases such as heart failure and pulmonary fibrosis. Proteomic profiling supports their mechanistic insights into ECM modulation.[1][2][3]

Therapeutic areas: PulmonologyCardiovascularOther
Modalities: Injectable ECM particles (biologics derived from human 3D cell cultures)Advanced immunotherapy approaches targeting the extracellular matrix (ECM)
Industry: Biotech

Partnerships

Brown University (R&D collaboration/support)[1]

Beyond the preview

Go deeper on Xm Biologics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xm Biologics.

Explore the full profile